EU Parliament Committee Adopts IMI2

The EU’s second Innovative Medicines Initiative will likely launch this year, following adoption of a regulation by the European Parliament’s industry and research committee.

IMI is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations aimed at furthering drug R&D, particularly in areas of unmet need. IMI2 will focus on target validation and biomarker research, innovative clinical trial paradigms, innovative therapeutic strategies, and patient-tailored adherence programs.

The regulation identifies 12 EU health priorities: antimicrobial resistance, osteoarthritis, cardiovascular disease, diabetes, neurodegenerative diseases, psychiatric diseases, respiratory diseases, autoimmune diseases, aging-related diseases, cancer, orphan diseases and vaccines.

IMI2 is expected to run until 2024. View the regulation at www.fdanews.com/ext/resources/files/04/04-17-14-IMI2.pdf. — Lena Freund

Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.